Entries |
Document | Title | Date |
20100279938 | Platelet Promoting Protein and The Usage Thereof - The present invention discloses a protein that has strong affinity to thrombopoietin receptor (C-MPL) and the nucleotide sequences of the protein. The protein is capable of increasing the numbers of platelets and enhancing the blood clotting in vivo and is named as platelet promoting protein (PPP). The protein and its nucleotide sequences can be used for the treatment of blood diseases including thrombocytopenia. | 11-04-2010 |
20100298221 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF - The present invention relates to novel 2-phenoxy-6-phenyl- and 2-phenoxy-6-pyridylnicotinic acid derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prophylaxis of cardiovascular disorders, especially of dyslipidemias, arteriosclerosis and heart failure. | 11-25-2010 |
20100298222 | USE OF AN AGENT THAT RESTORES TISSUE PERFUSION AND OXYGENATION - The presently disclosed subject matter provides methods for increasing perfusion in hypoxic regions of tissues in subjects. Also provided are methods for treating diseases and/or disorders associated with hypoxia in subjects, methods for increasing sensitivity of tumors to radiation and/or chemotherapy treatments, methods for delaying tumor growth in subjects, and methods for inhibiting tumor blood vessel growth in subjects. In some embodiments, the presently disclosed methods involve administering to subjects in need thereof a first composition selected from the group consisting of a nitrosylated hemoglobin and an agent that induces nitrosylation of endogenous hemoglobin in the subject and a second composition comprising a hyperoxic gas. In some embodiments, the presently disclosed methods also include treating a tumor with radiation therapy, chemotherapy, photodynamic therapy, immunotherapy, or combinations thereof. Also provided are inhalable gases that can be employed in the presently disclosed methods. | 11-25-2010 |
20100311657 | HEMOGLOBIN COMPOSITIONS - The invention provides compositions containing hemoglobin, particularly PEGylated hemoglobin. The PEGylated hemoglobin molecule is capable of transferring oxygen or carbon monoxide bound thereto to a tissue with which it is in proximity. Exemplary PEGylated hemoglobin formulations of the invention are virally inactivated. Various compositions of the invention include deoxygenated hemoglobin, which may be conjugated with one or more water-soluble polymer. PEGylated hemoglobin includes those species in which the iron atom of the hemoglobin molecule is not bound to oxygen or any other species, and hemoglobin molecules in which a species other than oxygen, e.g., carbon monoxide, is bound to the iron atom. The compositions of the invention are formulated as hypo-, iso- or hypertonic solutions of the PEGylated hemoglobin. The compositions are of use to treat and/or ameliorate disease, injury and insult by providing for the oxygenation of tissues and/organs. | 12-09-2010 |
20100317584 | PHARMACEUTICAL COMPOSITION, PACKAGE AND METHOD FOR RAPIDLY REDUCING THE URIC ACID IN BLOOD - The present invention relates to a pharmaceutical composition for rapidly reducing the uric acid level in blood in a subject, which comprises anserine in an amount of greater than 50 mg to about 600 mg. The present invention further relates to a package comprising the pharmaceutical composition comprising anserine, and a label and/or an insert indicating that the composition is administered to a subject to provide anserine in an amount of greater than 50 mg to about 600 mg per dose. In addition, the present invention relates to a method for rapidly reducing the uric acid level in blood in a subject, which comprises administering anserine in an amount of greater than 50 mg to about 600 mg to the subject. | 12-16-2010 |
20100323965 | Thrombopoietin Mimetics - The invention relates to compounds and their use in the treatment of thrombocytopenia resulting from diseases or conditions such as immune thrombocytopenic purpura, cancer chemotherapy, surgery, bone marrow or stem cell transplantation, radiation injury or treatment, chronic viral infection, and pancytopenia. The invention further relates to pharmaceutical compositions containing the compounds and compositions of the invention as well as methods for treating such diseases or conditions in a mammal, including a human, by administering to such mammal an effective amount of a selected thrombopoietin receptor agonist. | 12-23-2010 |
20110003751 | Novel Immunoregulatory Peptides, Compositions and Uses Thereof - A biologically active peptide, of Formula (1) [X-L-γ-Glu-Trp-Y], a novel pharmaceutical composition containing the peptide, a method for preparing the peptide and uses of the peptide are disclosed. | 01-06-2011 |
20110015127 | TARGETING COMPLEMENT FACTOR H FOR TREATMENT OF DISEASES - The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion. | 01-20-2011 |
20110059893 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS - The invention relates to compounds of structural formula (I): | 03-10-2011 |
20110092428 | DETECTING AND CONTROLLING ABNORMAL HEMATOPOIESIS - A method of detecting abnormal hematopoiesis in a subject based on abnormal expression of ZFP36L2, a method of controlling hematopoiesis in a subject altering the level or activity of ZFP36L2 protein in the subject, a method of screening for compounds that modulate hematopoiesis based on changes to ZFP36L2 expression, and compounds identified thereby. | 04-21-2011 |
20110118186 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF - The invention relates to synthetic peptide amides that are ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P | 05-19-2011 |
20110178018 | NOVEL SELENIUM-CONTAINING COMPOUNDS - A novel selenium-containing compound, a method of producing the selenium-containing compound, an analysis method using the selenium-containing compound, and use of the selenium-containing compound as an antioxidant, are disclosed. A novel selenium-containing compound shown by any of chemical formulas 1 to 4 is obtained by extracting a selenium-containing compound from a sample using an organic solvent or water, and purifying the selenium-containing compound. The novel selenium-containing compound may be used for a novel analysis method, or may be used as an antioxidant. | 07-21-2011 |
20110190207 | INHIBITING BINDING OF FGF23 TO THE BINARY FGFR-KLOTHO COMPLEX FOR THE TREATMENT OF HYPOPHOSPHATEMIA - The present invention is directed to a method of treating hypophosphatemia in a subject. This method involves selecting a subject with hypophosphatemia associated with elevated or normal FGF23 and administering to the selected subject an inhibitor of FGF23-Klotho-FGF receptor complex formation under conditions effective to treat the hypophosphatemia. The present invention is also directed to a method of screening for compounds suitable for treatment of hypophosphatemia associated with elevated or normal FGF23. This method involves providing FGF23, FGFR-Klotho complex, and one or more candidate compounds. The FGF23, the FGFR-Klotho complex, and the candidate compounds are combined under conditions effective for the FGF23 and the binary FGFR-Klotho complex to form a ternary complex if present by themselves. This method also involves identifying the candidate compounds, which prevent formation of the complex as being potentially suitable in treating hypophosphatemic conditions associated with elevated or normal FGF23. A method of screening the specificity of compounds which prevent formation of the FGF23-Klotho-FGFR complex is also disclosed. | 08-04-2011 |
20110190208 | MEDICAL USE OF THE RADICAL SCAVENGER AND ANTIOXIDANT ALPHA-1-MICROGLOBULIN - Medical use of alpha-1-microglobulin (A1M) in the treatment or prophylaxis of diseases wherein oxidative stress is a responsible factor in the progress of the disease. Notably, the present invention relates to the medical use of alpha-1-microglobulin in the treatment or prophylaxis of diseases or conditions associated with the presences of free radicals and/or free haemoglobin in the subject. | 08-04-2011 |
20110245176 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR - The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided. | 10-06-2011 |
20110275569 | PROTEASES TARGETING AGENTS - A protein inhibitor from | 11-10-2011 |
20110294737 | TERMINALLY-DIFFERENTIATED ANUCLEATE PLATELET PROGENY GENERATION - Platelets are induced to proliferate, form extensions and produce daughter cells by various methods, including culturing platelets under thrombocytopenic conditions. Expansion of platelet cell numbers increases the storage life of platelets. Modulation of RT activity can be used to produce new daughter platelets. Therefore, the invention provides a new therapeutic use for RT inhibitors that can now be used for treatment of thrombocytopenia and related disorders. Likewise, application of soluble protein factor that may be secreted and/or released by platelets cultured under thrombocytopenic conditions may also be used as a therapeutic agent to increase platelet numbers. | 12-01-2011 |
20110301088 | CRYSTALLINE EZATIOSTAT HYDROCHLORIDE ANSOLVATE - Crystalline ezatiostat hydrochloride ansolvate form D is more stable and/or more soluble that various solvated crystalline polymorphic forms of ezatiostat hydrochloride. | 12-08-2011 |
20120015881 | KALLIKREIN-INHIBITOR THERAPIES - Methods are described for preventing or reducing ischemia, e.g., cerebral ischemia, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia, in a patient. | 01-19-2012 |
20120021988 | METHODS FOR TREATING IMMUNE THROMBOCYTOPENIA - Polypeptides and other compounds that can bind specifically to the C | 01-26-2012 |
20120028899 | COMPOSITION AND PROCESS FOR SYNTHESIZING TENSE AND RELAXED STATE POLYMERIZED HEMOGLOBIN - Described herein is a composition and process for synthesizing a hemoglobin-based oxygen carrier (HBOC) composition that includes a polymerized hemoglobin locked in at least one of the tense or relaxed quaternary state and has a molecular weight of at least about 500 kDa. The PolyHb may have a cross-linker to hemoglobin molar ratio of at least about 20:1. The polymerized hemoglobin is useful for delivering oxygen to cells, such as for treatment of anemic conditions in a subject, perfusion of tissues or organs, and supplementing cell culture media in cell culturing systems. | 02-02-2012 |
20120065133 | Artificial Oxygen Transport Protein - This invention provides heme-containing peptides capable of binding molecular oxygen at room temperature. These compounds may be useful in the absorption of molecular oxygen from molecular oxygen-containing atmospheres. Also included in the invention are methods for treating an oxygen transport deficiency in a mammal. | 03-15-2012 |
20120094912 | MalPEG-Hb Conjugate-Containing Compositions for Delivering Carbon Monoxide (CO) to Cells - The present invention relates to compositions for delivering carbon monoxide (CO) to cells using heme proteins as carriers. In one embodiment, the present invention relates to the use of MalPEG surface modified hemoglobin to deliver CO to cells. | 04-19-2012 |
20120122785 | COMBINATION OF A LEUCINE SOURCE AND AN OMEGA- 3 UNSATURATED FATTY ACID SOURCE FOR USE IN THE TREATMENT OF HYPERCALCAEMIA - The present invention relates to a combination of a leucine source and at least one unsaturated fatty acid source for prophylactic or therapeutic treatment of hypercalcaemia. The invention further relates to a combination of a leucine source and at least one unsaturated fatty acid source for reducing or avoiding a reduction in bone mineral density in a subject or for in vivo regulating of the blood plasma calcium homeostasis. | 05-17-2012 |
20120172305 | RETRO-INVERSO PEPTIDES DERIVED FROM INTERLEUKIN-6 - This invention provides methods of treatment using retro-inverso peptides derived from interleukin-6 (IL-6) having between 15 and about 40 amino acids, and including the sequence that is retro-inverso with respect to SEQ ID NO 1, i.e. wherein said peptide comprises the sequence D-Glu-D-Ala-D-Met-D-Lys-D-Pro-D-Leu-D-Asn-D-Leu-D-Asn-D-Asn-D-Glu-D-Ala-D-Leu-D-Ala-D-Glu. The peptides of the invention have the same activity as native IL-6 and also have neurotrophic activity. The peptides of the invention are also less susceptible to proteolytic degradation in vivo because of their D-amino acid linkage. | 07-05-2012 |
20120184491 | Methods and Compound to Inhibit Ca2+ Permeable Cation Conductance - The present invention provides methods and compositions for inhibiting calcium permeable cation conductance of red blood cells from individuals afflicted with sickle cell anemia. The method comprises exposing the cells to the peptide GsMTx4 and/or variants thereof. | 07-19-2012 |
20120225818 | PLASMA PROTEIN EFFECTIVE FOR SUPPRESSING COUGH - The activated Factor XI is provided as an antitussive for cough caused by the stimulation at the tracheal bifurcation such as chronic cough. A pharmaceutical composition for prevention, treatment and/or symptom amelioration of cough, comprising a polypeptide chain as an active ingredient and a pharmaceutically acceptable carrier, wherein the polypeptide chain consists of a full length amino acid sequence constituting activated Factor XI (hereinafter also referred to as “FXIa”), the amino acid sequence with one or several amino acids therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences. | 09-06-2012 |
20120302503 | PEPTIDES FOR PREVENTING OR TREATING A DISEASE OR DISORDER ASSOCIATED WITH CBP OR p300 MISREGULATION, AND METHODS FOR USE AND IDENTIFICATION THEREOF - Described herein are therapeutic peptides composed of a cell penetrating peptide, a peptide derived from the sequence of c-Myb, and a peptide derived from the sequence of CREB, useful for the treatment or prevention of a disease or disorder associated with CBP or p300 misregulation. | 11-29-2012 |
20130029912 | TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, HEMOLYTIC ANEMIAS AND DISEASE STATES INVOLVING INTRAVASCULAR AND EXTRAVASCULAR HEMOLYSIS - Methods for treating subjects having complement-mediated hemolytic disorders, such as paroxysmal nocturnal hemoglobinuria (PNH) and other hemolytic anemias, the method comprising administering an effective amount of a composition that inhibits the activity of the complement alternative pathway. | 01-31-2013 |
20130040885 | COLLAGEN PAD - The present invention relates to a collagen pad and to processes for the manufacture thereof. One aspect of the invention provides a process for the manufacture of a collagen pad from a plurality of collagen particles, said process comprising steps of forming a dispersion of the collagen particles in an aqueous acid solution; and adding a flocculating agent to the dispersion to form a collagen floe. A further aspect of the invention provides a process for the manufacture of a collagen pad, wherein said process comprises a step of centrifuging the product of a flocculation reaction, said flocculation reaction comprising adding a flocculating agent to a dispersion of collagen particles in an aqueous acid solution to form a collagen floe. The collagen pad may be used, for example, in wound care. | 02-14-2013 |
20130053320 | TREATMENT OF ANEMIA BY ADNP AND ADNF POLYPEPTIDES - This invention relates to the use of ADNP, ADNP2, and ADNF polypeptides in the treatment of anemia and related conditions. Compositions of the ADNP, ADNP2, or ADNF polypeptides for such use are disclosed. Also provided are methods for concentrating or extracting ADNP, ADNP2, or ADNF polypeptides from dairy products and the use of dairy products in the context of treating anemia. | 02-28-2013 |
20130059783 | COMPOSITIONS AND METHODS FOR EXPANDING BFU-E CELLS - The invention provides methods of expanding BFU-E cells comprising contacting one or more BFU-E cells with a hypoxia inducible factor 1 activator and a glucocorticoid receptor (GR) activator, e.g., a GR agonist. In some embodiments, the FIIF-1 activator is a prolyl hydroxylase inhibitor (PHI). In some embodiments, the method comprises culturing BFU-E in medium containing a HIF-1a activator and a glucocorticoid receptor (GR) activator, e.g., a GR agonist. In some embodiments the BFU-E cells are human cells. The invention provides cell culture media useful for expanding BFU-Es, wherein the cell culture media comprise a HIF-1 activator and a GR activator (e.g., a GR agonist) The invention provides a method comprises administering a HIF-1 activator and a GR agonist to a subject in need thereof. In some embodiments, the subject suffers from anemia. In some embodiments, the anemia is an Epo-resistant anemia. In some embodiments, the anemia is Diamond-Blackfan anemia. | 03-07-2013 |
20130079283 | Erythropoitein Receptor Peptide Formulations and Uses - The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided. | 03-28-2013 |
20130085109 | METHODS OF CARDIOVASCULAR PATIENT TREATMENT USING SUBSTANCES SUFFICIENT TO REDUCE ACTIN DEPOLYMERIZATION - Methods of cardiovascular patient treatment using substances sufficient to reduce actin depolymerization. In an exemplary embodiment of a method of treating a patient of the present disclosure, the method comprises the step of administering a therapeutically effective dose of a substance that reduces actin depolymerization within a vasculature of a patient to treat a cardiovascular condition of the patient. In at least one embodiment, the substance the substance is selected from the group consisting of jasplakinolide, Jasplaskinolide V, and Amphidinolide H. | 04-04-2013 |
20130143817 | USE OF TRANSFERRIN IN TREATMENT OF BETA-THALASSEMIAS - Disclosed herein are methods for treating disease, such as diseases of iron overload, including β-thalassemia, comprising administering at least one course of transferrin and thereby reducing the size of the spleen in said patient and reducing the concentration of iron in the tissues and blood. | 06-06-2013 |
20130150301 | THERAPEUTIC AGENTS FOR REGULATING SERUM PHOSPHORUS - Methods for modulating serum phosphorus levels are described, wherein calcimimetic agents are administered to a subject in need thereof. In one embodiment, the compound is cinacalcet, and in other embodiments the compound is comprised of a contiguous sequence of subunits, X | 06-13-2013 |
20130190241 | NOVEL BIOLOGICALLY ACTIVE PEPTIDES AND THEIR NEW USES - Novel peptides are disclosed with their use as a pharmaceutical composition. A method is also disclosed for making pharmaceutical compositions and treatment of an individual. | 07-25-2013 |
20130244939 | NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR - The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided. | 09-19-2013 |
20130267465 | COLLAGENOUS MATERIAL - A process for the manufacture of a collagenous material from a plurality of collagen particles is described. The collagen particles are derived from a natural tissue material, are substantially free of non-fibrous tissue proteins, cellular elements and lipids or lipid residues, and comprise fragments of collagen fibres displaying original collagen fibre architecture and molecular ultrastructure of the natural tissue material. The process comprises the step of freeze drying the collagen particles in suspension in a freeze-drying suspension medium. | 10-10-2013 |
20130331327 | Variant Beta2-microglobulin, characterization of the same and applications thereof - This invention relates to the specific Asp76Asn (D76N) variant β | 12-12-2013 |
20140031292 | Yeast Cell Surface Display of Proteins and Uses Thereof - The present invention provides a genetic method of tethering polypeptides to the yeast cell wall in a form accessible for binding to macromolecules. Combining this method with fluorescence-activated cell sorting provides a means of selecting proteins with increased or decreased affinity for another molecule, altered specificity, or conditional binding. As one embodiment, attaching an scFv antibody fragment to the Aga2p agglutinin effectively mimics the cell surface display of antibodies by B cells in the immune system for affinity maturation in vivo. As another embodiment, T cell receptor mutants can be isolated by this method that are efficiently displayed on the yeast cell surface, providing a means of altering T cell receptor binding affinity and specificity by library screening. | 01-30-2014 |
20140073572 | TARGETING COMPLEMENT FACTOR H FOR TREATMENT OF DISEASES - The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion. | 03-13-2014 |
20140107031 | TEMPLATE-FIXED PEPTIDOMIMETICS - Template-fixed β-hairpin peptidomimetics of the general formula | 04-17-2014 |
20140213521 | Oral Treatment of Inflammatory Bowel Disease - The present invention relates to treatment of an inflammatory bowel disease by simultaneous or successive parental and oral administration of a mammalian beta defensin. | 07-31-2014 |
20140256637 | ROMIDEPSIN SOLID FORMS AND USES THEREOF - The present disclosure provides solid forms of a compound of formula I. In some embodiments, the present disclosure provides crystalline forms of Compound I. In some embodiments, the present disclosure provides solvate forms of Compound I. In some embodiments, the present disclosure provides amorphous Compound I. | 09-11-2014 |
20140315812 | AMORPHOUS EZATIOSTAT ANSOLVATE - Provided herein is an amorphous form of a pharmaceutically acceptable salt of ezatiostat, for example, ezatiostat hydrochloride, compositions, uses and methods of preparation thereof. | 10-23-2014 |
20140315813 | Use of an Active Biological Substance in Abnormal Cellular and Viral Membrane Physiologies - An active biological substance is disclosed for use in abnormal cellular and viral membrane physiologies in human and mammal organisms. The active substance has diagnostic and/or therapeutic properties and contains or consists of at least one component selected from the group of substances including: histones, covalently modified histones, histone-like polypeptides, biologically active histone sequences and histone-like polypeptides as agents for stopping the supply to solid tumours over their blood vessels, for killing cells infected by virus and for killing tumour cells with disturbed lipid asymmetry. | 10-23-2014 |
20140323403 | HEMOGLOBIN COMPOSITIONS AND METHODS OF USE - A modified hemoglobin oxygen transport agent useful in the treatment of hypoxia and related conditions is disclosed. The composition consists primarily of carbohydrate shielded hemoglobin or a hybrid hemoglobin molecule to deliver oxygen in hypoxia stage. The carbohydrate shielded hemoglobin therapy is based on oxidation physiology, which is believed to play key roles in ischemia, anemia and other conditions related to hypoxia. | 10-30-2014 |
20140329754 | COMPOSITIONS AND METHODS FOR TREATING MYELODYSPLASTIC SYNDROME - This invention generally relates to compositions and methods for treating myelodysplastic syndrome. In one embodiment, this invention relates to methods for treating myelodysplastic syndrome with ezatiostat or a salt thereof and lenalidomide. | 11-06-2014 |
20140342986 | Compositions and methods for treating diseases - This invention relates to compositions and methods for treatment of vascular conditions. The invention provides arginine polymers and arginine homopolymers for the treatment and/or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing. The invention also provides arginine polymers and arginine homopolymers for use in organ perfusate and preservation solutions. | 11-20-2014 |
20140371149 | SCARRING REDUCING WOUND TREATMENT - The present invention refers to the use of hemoglobin or myoglobin charged with a non-oxygen ligand for improved scarring of wounds. | 12-18-2014 |
20150011474 | POLYPEPTIDES BINDING TO HUMAN COMPLEMENT C5 - The present invention relates to C5 binding polypeptides, comprising a C5 binding motif, BM, which motif consists of an amino acid sequence selected from i) EX | 01-08-2015 |
20150018277 | Combination of a Leucine Source and an Omega-3 Unsaturated Fatty Acid Source for Use in the Treatment of Hypercalcaemia - The present invention relates to a combination of a leucine source and at least one unsaturated fatty acid source for prophylactic or therapeutic treatment of hypercalcaemia. The invention further relates to a combination of a leucine source and at least one unsaturated fatty acid source for reducing or avoiding a reduction in bone mineral density in a subject or for in vivo regulating of the blood plasma calcium homeostasis. | 01-15-2015 |
20150031618 | MUTEINS OF A1M LIPOCALIN AND METHOD OF PRODUCTION THEREFOR - The present disclosure relates to a collection of novel muteins derived from human α1m (or a1m) polypeptide or a functional homologue thereof. The disclosure further refers to a α1m mutein capable of specifically binding to one or more targets other than a target to which wild-type α1m binds. The disclosure also relates to a method for producing such collection of muteins and a method for isolating a mutein capable of binding one or more such non-natural targets of wild-type α1m polypeptide. These aspects are made possible due to, e.g, the structural elucidation of α1m disclosed herein by the present inventors, an appreciation of ligand-binding sights thereof and, hence, an understanding of which amino acid positions are most suitable for mutagenesis for re-engineering specificity and affinity for any given target while maintaining the secondary and/or tertiary structure of α1m. | 01-29-2015 |
20150087591 | Novel Composition for Extracorporeal Reduction of Beta-Amyloids and Process for Producing Thereof - The present invention provides a safe, reliable, and economical process for preparing an improved dialysis fluid formulation effective for extracorporeal treatment, through a blood filtration process, of a Beta-Amyloid associated pathological condition in a subject, said process comprises preparing a composition comprising KLVFF peptide, or a variant thereof, as the capturing and binding agent, and a carrier therefor, and mixing said composition with a dialysate solution. The process utilizes a compact, inexpensive, and simple standard dialysis machine that extracorporeally removes Beta-Amyloids without allowing escape of the Beta-Amyloids back into a subject's body, without having to intricately evaluate the performance and characteristics of a dialysis membrane, and without putting the health condition of the subject at risk. | 03-26-2015 |
20150087592 | Sugar Compositions for Treating Hemophilia A and/or Von Willebrand Disease - The invention relates to compositions comprising an isolated sugar for use in the treatment of von Willebrand disease and/or hemophilia A, wherein the sugar is an accessible sugar residue derived from ABO(H) blood group antigen. | 03-26-2015 |
20150094268 | Prophylactic or therapeutic agent for hepatic diseases - The present invention provides a prophylactic or therapeutic agent for a hepatic disease, containing AIM or a partial peptide thereof, or a nucleic acid containing a base sequence encoding the same, a method of screening for a prophylactic or therapeutic agent for a hepatic disease, comprising using an0 animal obtained by loading a non-human mammal deficient in AIM expression with a high fat diet and the like. | 04-02-2015 |
20150119331 | Use of Histones for Therapeutic Purposes - The invention relates to the use of at least one human recombinant histone, especially at least one histone H1 subtype, and/or a therapeutic histone fraction as a basis for the treatment of thrombocytopenia. | 04-30-2015 |
20150133386 | Glutathione-Elevating Compositions And Uses Thereof - Compositions and methods for treating blood disorders associated with glutathione dysregulation, utilizing short thiol-containing peptides selected from the group consisting of Cys-Lys-Met-Cys (SEQ ID NO: 1), Cys-Met-Lys-Cys (SEQ ID NO: 2) and Cys-β-Ala-His-Cys (SEQ ID NO: 3). Compositions and methods for preserving biological samples using the peptides. Use of synthetic thiol-containing peptides as highly effective therapeutic and protective agents in clinical and research applications where lifespan and/or viability and functioning of cells is compromised at least partially due to depletion of reduced glutathione, or where viability and functioning of cells can be improved by elevating reduced glutathione levels. | 05-14-2015 |
20150141341 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF BETA-THALASSEMIA - Methods and compositions for the treatment of β-thalassemia are provided. Methods and compositions restore or increase erythrocyte maturation in individuals afflicted with β-TM by preventing proteolysis of GATA-1 protein. Screening methods for identifying agents which bind heat shock protein 70 (HSP-70) and inhibit HSP-70 α-globin binding, but which allow GATA-1 protein-HSP-1 binding in a manner that prevents GATA-1 proteolysis. | 05-21-2015 |
20150148296 | AGENT FOR PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF PERIPHERAL NEUROPATHIC PAIN CAUSED BY ANTICANCER AGENT - A medicament effective for prophylactic and/or therapeutic treatment of a peripheral neuropathic pain such as allodynia caused by a treatment with an anticancer agent, which comprises thrombomodulin as an active ingredient. | 05-28-2015 |
20160015795 | C1-INH COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF DISORDERS ASSOCIATED WITH C1 ESTERASE INHIBITOR DEFICIENCY - Compositions and methods for the treatment and/or prevention of disorders associated with C1 esterase inhibitor deficiency are disclosed. | 01-21-2016 |
20160015855 | SURGICAL METHODS EMPLOYING PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS - Compositions, methods and delivery devices (e.g., pre-filled syringes) for controlling bleeding during surgical procedures are provided, wherein the compositions are characterized as having an aqueous formulation that is capable of adopting a gelled state upon contact with bodily fluids and/or blood of a patient (i.e., physiological conditions). | 01-21-2016 |
20160022758 | AGENT DERIVED FROM TORTOISE SPLEEN STIMULATING MAMMALIAN HEMOPOIESIS - The present invention relates to a proteinaceous extract derived from tortoise spleen and to a tetrapeptide FTGN, which have stimulatory activity on hematopoietic cells. In particular, this tetrapeptide enhances hemopoietic reconstruction, and bone marrow re-population, reduced as a consequence of a high dose of radiation or chemotherapy exposure. The invention further provides pharmaceutical compositions comprising as an effective ingredient the proteinaceous extract or the FTGN tetrapeptide and ex vivo and in vivo methods of treatment employing them. | 01-28-2016 |
20160022783 | POLYALKYLENE OXIDE VALERATE HEMOGLOBIN CONJUGATES - The present invention relates generally to polyethylene glycol (PEG) conjugated hemoglobins made by conjugation of succinimidyl-valerate activated polyethylene glycol to primary amines and N-terminal valines of the hemoglobin. | 01-28-2016 |
20160039910 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARBOXYHEMOGLOBINEMIA - Described herein is a new antidote for the rapid elimination of carbon monoxide from hemoglobin, including brain, heart, and red cell hemoglobin. The disclosed therapy involves the use of modified human globins, particularly neuroglobins modified at residue 64 and cytoglobins modified at residue 81, which bind carbon monoxide with extremely high affinity. The monomeric mutant globins are infused into blood, where they rapidly and irreversibly sequester carbon monoxide, and thus limit toxic effects of carbon monoxide on cellular respiration and oxygen transport and utilization. | 02-11-2016 |
20160096870 | COMPLEMENT INHIBITORS - The invention relates to complement inhibitors that inhibit both the classical and alternative complement pathways. In particular, the invention relates to complement inhibitors derived from the salivary glands of haematophagous arthropods that inhibit both the classical and alternative complement pathways. The invention also relates to the use of such complement inhibitors in the treatment and prevention of diseases. | 04-07-2016 |
20160130312 | Bis-Met Histones - The present invention provides a nucleic acid molecule which encodes a polypeptide consisting of two methionine residues as the first and second N-terminal amino acid residues linked via a peptide bond to a mature eukaryotic histone. The present invention furthermore relates to a vector containing said nucleic acid molecule, a host transformed with said vector, polypeptides encoded by the nucleic acid molecule and pharmaceutical and diagnostic compositions. The present invention also relates to the use of the nucleic acid molecule, vectors, hosts and the polypeptide of the invention for the preparation of a composition for the treatment of diseases. Furthermore, the present invention relates to a method of testing for the presence of the nucleic acid molecule or the polypeptide in a sample and to a kit. | 05-12-2016 |
20160130313 | Bis-Met Histones - The present invention provides a nucleic acid molecule which encodes a polypeptide consisting of two methionine residues as the first and second N-terminal amino acid residues linked via a peptide bond to a mature eukaryotic histone. The present invention furthermore relates to a vector containing said nucleic acid molecule, a host transformed with said vector, polypeptides encoded by the nucleic acid molecule and pharmaceutical and diagnostic compositions. The present invention also relates to the use of the nucleic acid molecule, vectors, hosts and the polypeptide of the invention for the preparation of a composition for the treatment of diseases. Furthermore, the present invention relates to a method of testing for the presence of the nucleic acid molecule or the polypeptide in a sample and to a kit. | 05-12-2016 |
20160175403 | SCARRING REDUCING WOUND TREATMENT | 06-23-2016 |
20160184404 | NOVEL HEMOGLOBIN-DERIVED PEPTIDE BASED PHARMACEUTICAL COMPOSITIONS - The present invention relates to a pharmaceutical composition comprising at least one Toll-like receptor (TLR)-activating amphiphilic lipid and at least one hemoglobin-derived peptide and optionally a pharmaceutically acceptable carrier. The present invention also relates to the pharmaceutical composition according to the invention for use in preventing and/or treating tumours, preventing and/or treating infections, preventing and/or treating allergies, preventing and/or treating age-related immune imbalances, stimulating the innate and adaptive immune system and/or alleviating the adverse side effects of irradiation. Moreover, the present invention also relates to a hemoglobin-derived peptide as well as its use in treating a bacterial infection. | 06-30-2016 |